Ideaya Biosciences Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Ideaya Biosciences Inc 's ROA in the second quarter of 2026?
Ideaya Biosciences Inc recorded a cumulative net loss of $-175 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -15.23%.

However, within the Healthcare sector 333 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3294, from total ROA ranking in the first quarter of 2026 at 3758.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	26.95 %	-29.5 %	0.07 %	-4.73 %	4.85 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-175	-140	-114	-161	-332
Return On Assets (TTM)	-15.23 %	-12.96 %	-9.57 %	-13.53 %	-27.59 %
IDYA's Total Ranking	# 3294	# 3758	# 3414	# 3772	# 3799
Total Assets (TTM) in million	1,294	1,030	1,109	1,164	1,020
Seq. Total Assets Change	25.62 %	-7.12 %	-4.68 %	14.15 %	-30.24 %
Seq. Net Income Change	-	-	-	-	-

IDYA's 5 Years Annual ROA >> Back to IDYA Management Effectiveness >> Compare IDYA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 119
Sector	# 334
Overall	# 3324

Return On Assets Statistics
High	Average	Low
-9.58 %	-19.6 %	-37.79 %
(Jun 30 2021)		(Mar 31 2020)

Financial Statements
Ideaya Biosciences Inc 's Assets	$ 1,294 million	IDYA's Balance sheet
Ideaya Biosciences Inc 's Income	$ -112 million	Quarterly IDYA's Income Statement
IDYA's Income by Division		See IDYA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	37.09 %	70.99 %	67.83 %	1.64 %	29.32 %
Total Assets in million	1,520	1,109	648	386	380
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-114	-274	-113	-59	-50
Annual Return On Assets	-7.48 %	-24.76 %	-17.42 %	-15.18 %	-13.09 %

IDYA's 5 Years Annual ROA >> Back to IDYA Management Effectiveness >> Compare IDYA ROA to its Competitors

More Return On Assets Ratios
IDYA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
IDYA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for IDYA's Competitors
Subscribers only: Roa for Ideaya Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for IDYA's Customers

You may also want to know
IDYA's Roi	IDYA's Inventory Turnover Ratio	IDYA's Growth Rates	IDYA's Dividend Comparisons
	IDYA's Profitability Ratios	IDYA's Asset Turnover Ratio	IDYA's Dividend Growth
IDYA's Roe	IDYA's Valuation Ratios	IDYA's Financial Strength Ratios	IDYA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-30T22:00:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.